Acadia Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Corcept Therapeutics USD 83.37M 9.63M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
Eisai JPY 104.52B 7.1B 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Intra Cellular Therapies USD 137.73M 5.63M 2024-12
J&J USD 6.45B 975M 2024-12
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Prothena USD 16.85M 88K 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Acadia Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.